- Home
- KALU vs OCS Comparison
KALU vs OCS Comparison
Compare KALU & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALU | OCS |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | KALU | OCS |
|---|---|---|
| Price | $130.89 | $27.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $107.00 | $40.14 |
| AVG Volume (30 Days) | 219.5K | ★ 295.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 6.77 | N/A |
| Revenue | ★ $1,585,900,000.00 | N/A |
| Revenue This Year | $18.71 | $418.43 |
| Revenue Next Year | $1.97 | $892.34 |
| P/E Ratio | $19.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.81 | $14.00 |
| 52 Week High | $150.00 | $30.68 |
Technical Indicators
Market Signals| Indicator | KALU | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 48.09 |
| Support Level | $116.89 | $19.00 |
| Resistance Level | $135.48 | $29.23 |
| Average True Range (ATR) | 7.85 | 0.94 |
| MACD | -0.92 | -0.37 |
| Stochastic Oscillator | 42.09 | 17.31 |
Price Performance
Historical ComparisonAbout KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.